SOLODYN

Compare SOLODYN  to:
Compare
Compare

Generic Name for SOLODYN

Minocycline (as HCl) 45mg, 90mg, 135mg; ext-rel tabs.

Legal Classification:

Rx

Pharmacological Class for SOLODYN

Tetracycline antibiotic.

Manufacturer of SOLODYN

Medicis Pharmaceuticals Corp

Indications for SOLODYN

Inflammatory lesions of non-nodular moderate to severe acne.

Adult dose for SOLODYN

Swallow whole. Give once daily for up to 12 weeks. Dose based on weight: approximately 1mg/kg. 45–59kg: 45mg. 60–90kg: 90mg. 91–136kg: 135mg. Renal impairment: reduce dose or extend dosing intervals.

Children's dosing for SOLODYN

Not recommended.

Warnings/Precautions for SOLODYN

Not interchangeable with other minocycline products. Renal or hepatic impairment. Monitor blood, renal, or hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for SOLODYN

Antacids, iron, zinc, calcium, magnesium, urinary alkalinizers reduce absorption. Avoid penicillins, methoxyflurane, isotretinoin. Monitor PT with oral anticoagulants. May antagonize oral contraceptives.

Adverse Reactions for SOLODYN

Headache, fatigue, dizziness, GI upset, rash, increased BUN, hepatotoxicity, tinnitus, tooth discoloration, pseudotumor cerebri, photosensitivity, hyperpigmentation, autoimmune syndromes.

How is SOLODYN supplied?

Tabs—30, 90, 100

Related Disease:

Acne

Related Resources

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Differin Lotion approved for acne

March 22, 2010

Galderma's Differin product line has been expanded with the FDA approval of Differin Lotion (adapalene lotion) 0.1% for the treatment of acne vulgaris in patients ≥12 years of age.

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

BenzEFoam available for acne vulgaris

October 01, 2009

Onset Therapeutics has launched BenzEFoam (benzoyl peroxide 5.3%) emollient foam for the topical treatment of mild to moderate acne vulgaris.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions